1-4 of 4
Susan Lattimore
Close
Sort by
Journal Articles

Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up

Steven W. Pipe, Frank W.G. Leebeek, Michael Recht, Nigel S. Key, Susan Lattimore, Giancarlo Castaman, Michiel Coppens, David Cooper, Robert Gut, Sergio Slawka, Stephanie Verweij, Ricardo Dolmetsch, Yanyan Li, Paul E. Monahan, Wolfgang A. Miesbach
Journal: Blood
Blood (2022) 140 (Supplement 1): 4910–4912.
https://doi.org/10.1182/blood-2022-166135
Published: 2022
Journal Articles

Durability of Bleeding Protection and Factor IX Activity Levels Are Demonstrated in Individuals with and without Adeno-Associated Virus Serotype 5 Neutralizing Antibodies (Titers <1:700) with Comparable Safety in the Phase 3 HOPE-B Clinical Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B

Steven W. Pipe, Frank W.G. Leebeek, Michael Recht, Nigel S. Key, Susan Lattimore, Giancarlo Castaman, David Cooper, Stephanie Verweij, Ricardo Dolmetsch, Jacqueline Tarrant, Yanyan Li, Paul E. Monahan, Wolfgang A. Miesbach
Journal: Blood
Blood (2022) 140 (Supplement 1): 4904–4906.
https://doi.org/10.1182/blood-2022-166745
Published: 2022
Journal Articles

Decreased Skeletal Health Negatively Impacts Quality of Life of People with Hemophilia

Galen Goldscheitter, BS, BA, Susan Lattimore, Jason A Taylor, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1207.
https://doi.org/10.1182/blood-2018-99-113086
Published: 2018
Journal Articles

Identification of Qualitative Platelet Disorders in Adolescent Women with Heavy Menstrual Bleeding

Kristina M. Haley, DO, Susan Lattimore, RN, Cara McDavitt, Ayesha Khader, Colin Boehnlein, Sandra Baker-Groberg, PhD, Anh Ngo, Owen J.T. McCarty, PhD, Michael Recht, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4922.
https://doi.org/10.1182/blood.V128.22.4922.4922
Published: 2016